Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe
Observational · No treatment assigned · 1 site · Centre Hospitalier Universitaire de la Guadeloupe
Official record & contacts on ClinicalTrials.gov ↗
In plain English
What this trial is testing
Condition(s) listed: HELICOBACTER PYLORI INFECTIONS and Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis). This is an observational study: researchers collect information (for example questionnaires, samples, or scans) but the study does not assign a treatment.
Who can join
- Ages 18 and older
- Any sex
Some of the main requirements, copied from the record:
- Patients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and/or serology at the time of diagnosis of IBD Patients affiliated to the…
There are also 1 reasons someone might not be able to join (exclusion criteria). Only the trial team can confirm whether you qualify.
What's involved
- About 100 participants are expected to take part.
- Start date: 2025-12-15 (planned).
- Main results expected around 2026-12-15 (estimate from the record).
- 1 study site listed in Guadeloupe.
Main thing being measured
- Prevalence of H. pylori infection in patients with Inflammatory Bowel Disease (IBD) (At the time of endoscopic evaluation (baseline only).)
In the researchers’ words
Clinical and experimental data suggest that dysbiosis may play a pivotal role in the pathogenesis of intestinal bowel disease (IBD). However, to the best of our knowledge, the composition of gastric and of intestinal microbiome has never been investigated in a population with IBD according to the presence/absence of Helicobacter pylori (H. pylori) in the stomach.
This is a short automatic summary built from the official record. A fuller plain-English card is coming; until then, please read the official record.
Questions to ask your doctor and the trial team
- Am I likely to qualify, given my health history?
- What would I have to do, and how often would I need to visit?
- Could I get a placebo? What happens to my current treatment?
- What are the possible risks and benefits?
- Are travel or other costs covered?
- What happens after the trial ends?
Official details
| Status | Not yet recruiting |
|---|---|
| Phase | Observational |
| Study type | Observational |
| Conditions | HELICOBACTER PYLORI INFECTIONS; Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) |
| Lead sponsor | Centre Hospitalier Universitaire de la Guadeloupe |
| Enrollment | 100 (estimated) |
| Start date | 2025-12-15 |
| Primary completion (est.) | 2026-12-15 |
| First posted | 2025-12-18 |
| Last updated | 2025-12-18 |
| Official title | Prevalence of Helicobacter Pylori on Patients With Chronic Inflammatory Bowel Disease (IBD) at the CHU of Guadeloupe |
| ClinicalTrials.gov ID | NCT07292454 |
Interventions
- Biopsies (Other)
Gastric biopsies are taken during digestive endoscopy as part of routine clinical care. Two additional biopsies (one fundic and one antral) are planned for research purposes, specifically for metagenomic analysis of the gastric microbiome.
Full eligibility criteria (from the record)
Inclusion Criteria: Patients over 18 years old Patients with IBD from the CHU of Guadeloupe Patients benefiting from an investigation of H. pylori infection through gastric biopsies and/or serology at the time of diagnosis of IBD Patients affiliated to the French social security system Free informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research) Exclusion Criteria: Patients of less than18 years Patients having not given their writing informed consent
Locations (1)
| Site | City | Country | Site status |
|---|---|---|---|
| CHU de la Guadeloupe | Pointe-à-Pitre, CHU de La Guadeloupe | Guadeloupe |
For contacts at each site, use the official record.
Information only, not medical advice. Talk to your doctor and the trial team before making any decision about a clinical trial.